Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells

References

• Cao H-H, Chu J-H, Kwan H-Y, et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Sci Rep. 2016;6(1):1–12.
   PubMedGoogle Scholar
• Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol. 2010;49(9):978–986.
   PubMed Web of Science ®Google Scholar
• Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res. 2009;22(4):388–399.
   PubMed Web of Science ®Google Scholar
• Chen Y, Bathula SR, Yang Q, et al. Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol. 2010;130(12):2790–2798.
   PubMed Web of Science ®Google Scholar
• Li L, Hou J, Liu X, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35(12):3840–3850.
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang J, Peng L. (-)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway. Oncol Rep. 2017;37(1):483–491.
   PubMed Web of Science ®Google Scholar
• Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005;16(6):601–607.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim A, Miyata K, et al. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev. 2016;104:61–77.
   PubMed Web of Science ®Google Scholar
• Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–116.
   PubMed Web of Science ®Google Scholar
• Kim S-S, Garg H, Joshi A, et al. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med. 2009;15(11):491–500.
   PubMed Web of Science ®Google Scholar
• Montier T, Benvegnu T, Jaffrès P-A, et al. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther. 2008;8(5):296–312.
   PubMed Web of Science ®Google Scholar
• Vakhshiteh F, Khabazian E, Atyabi F, et al. Peptide-conjugated liposomes for targeted miR-34a delivery to suppress breast cancer and cancer stem-like population. J Drug Deliv Sci Technol. 2020;57:101687.
   Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129–138.
   PubMed Web of Science ®Google Scholar
• Shroff K, Kokkoli E. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells. Langmuir. 2012;28(10):4729–4736.
   PubMed Web of Science ®Google Scholar
• Vllasaliu D, Fowler R, Stolnik S. PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin Drug Deliv. 2014;11(1):139–154.
   PubMed Web of Science ®Google Scholar
• Mondal G, Barui S, Chaudhuri A. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor. Biomaterials. 2013;34(26):6249–6260.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Hatakeyama H, Sato Y, et al. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J Control Release. 2014;173:110–118.
   PubMed Web of Science ®Google Scholar
• Chen C-W, Lu D-W, Yeh M-K, et al. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine. 2011;6:2567–2580.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Murthy R. Use of electrolyte induced flocculation technique for an in vitro steric stability study of steric stabilized liposome formulations. Pharmazie. 2004;59(1):74–76.
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Besaratinia A. UV wavelength-dependent DNA damage and human non-melanoma and melanoma skin cancer. Photochem Photobiol Sci. 2012;11(1):90–97.
   PubMed Web of Science ®Google Scholar
• Lakshmikuttyamma A, Sun Y, Lu B, et al. Stable and efficient transfection of siRNA for mutated KRAS silencing using novel hybrid nanoparticles. Mol Pharm. 2014;11(12):4415–4424.
   PubMed Web of Science ®Google Scholar
• Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187–200.
   PubMedGoogle Scholar
• Gao Y, Liu X-L, Li X-R. Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine. 2011;6:1017–1025.
   PubMed Web of Science ®Google Scholar
• Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114(1):100–109.
   PubMed Web of Science ®Google Scholar
• Li W, Szoka FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res. 2007;24(3):438–449.
   PubMed Web of Science ®Google Scholar
• Kooijmans S, Fliervoet L, Van Der Meel R, et al. PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time. J Control Release. 2016;224:77–85.
   PubMed Web of Science ®Google Scholar
• Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143(2):274–279.
   PubMed Web of Science ®Google Scholar
• Xia Y, Tian J, Chen X. Effect of surface properties on liposomal siRNA delivery. Biomaterials. 2016;79:56–68.
   PubMed Web of Science ®Google Scholar
• Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90(6):667–680.
   PubMed Web of Science ®Google Scholar
• Khatri N, Baradia D, Vhora I, et al. Development and characterization of siRNA lipoplexes: effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study. AAPS PharmSciTech. 2014;15(6):1630–1643.
   PubMed Web of Science ®Google Scholar
• Javali NM, Raj A, Saraf P, et al. Fatty acid-RGD peptide amphiphile micelles as potential paclitaxel delivery carriers to α(v)β3 integrin overexpressing tumors. Pharm Res. 2012;29(12):3347–3361.
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005;24(2):315–327.
   PubMed Web of Science ®Google Scholar
• Fu X, Yang Y, Li X, et al. RGD peptide-conjugated selenium nanoparticles: antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomedicine. 2016;12(6):1627–1639.
   PubMed Web of Science ®Google Scholar
• Alshamsan A, Hamdy S, Samuel J, et al. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials. 2010;31(6):1420–1428.
   PubMed Web of Science ®Google Scholar
• Ren Y, Yuan B, Hou S, et al. Delivery of RGD-modified liposome as a targeted colorectal carcinoma therapy and its autophagy mechanism. J Drug Target. 2021;29:1–12.
   PubMed Web of Science ®Google Scholar
• Nik ME, Malaekeh-Nikouei B, Amin M, et al. Liposomal formulation of galbanic acid improved therapeutic efficacy of pegylated liposomal doxorubicin in mouse colon carcinoma. Sci Rep. 2019;9(1):1–15.
   PubMedGoogle Scholar
• Shuhendler AJ, Prasad P, Leung M, et al. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater. 2012;1(5):600–608.
   PubMed Web of Science ®Google Scholar
• Shan D, Li J, Cai P, et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 2015;5(1):15–26.
   PubMed Web of Science ®Google Scholar
• Cui J, Alt K, Ju Y, et al. Ligand-functionalized poly(ethylene glycol) particles for tumor targeting and intracellular uptake. Biomacromolecules. 2019;20(9):3592–3600.
   PubMed Web of Science ®Google Scholar
• Noh GJ, Oh KT, Youn YS, et al. Cyclic RGD-conjugated hyaluronate dot bearing cleavable doxorubicin for multivalent tumor targeting. Biomacromolecules. 2020;21(6):2525–2535.
   PubMed Web of Science ®Google Scholar